Making a Nobel-winning chemistry reaction even better
New catalyst offers greater control over the synthesis of organic cyclic compounds, including potential cancer drugs.
Pfizer expands its research footprint in Cambridge
Announces lease of space in building being developed by MIT
Five companies join the Center for Biomedical Innovation's NEWDIGS program
Bristol‐Myers Squibb, Johnson & Johnson, Life Technologies, Pfizer and Quintiles will support initiatives in regulatory science and oncology innovation.
More than just a pretty flower
MIT chemists engineer the periwinkle plant to produce compounds that could become more effective cancer drugs.
Nerve-cell regeneration quest is fast tracked
Microchip technology rapidly identifies compounds for regrowing nerves, in live animals.
Squeezing more production out of bacteria
MIT chemical engineers demonstrate a new way to dramatically boost bacteria’s manufacturing abilities.
From sponges, a potential cancer drug
MIT chemists have synthesized a family of natural compounds that have shown promise in killing tumor cells.
Why saliva forms beads on a string
Researchers’ solution to longstanding mystery could enable better inkjet printing and drug-dispensing systems.
MIT’s Koch Institute in strategic partnership with Ortho-McNeil-Janssen Pharmaceuticals
Organizations will collaborate in multiple areas of oncology research and technology development.
An easier way to synthesize new drug candidates
MIT chemists’ answer to long-standing problem could have a big impact on pharmaceutical business.
Why cancer drugs lose their power
MIT biologists show how tumors can become resistant to the commonly used chemotherapy drug cisplatin.
Biomanufacturing Research Program wins grant from Sloan Foundation
Will be used to examine globalization and regulatory compliance
